NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

Company Overview

NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Key Stats

• Today's Range: $0.69 to $0.76
• 50-Day Range: N/A
• 52-Week Range: $0.36 to $9.08
• Volume: 167,262 shs
• Average Volume: 881,606 shs
• Market Capitalization: $2.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NovaBay Pharmaceuticals Stock Analysis - MarketRank™

NovaBay Pharmaceuticals scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for NovaBay Pharmaceuticals.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($2.54) to ($0.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NovaBay Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NovaBay Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NovaBay Pharmaceuticals has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.49% of the outstanding shares of NovaBay Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

NovaBay Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NovaBay Pharmaceuticals has recently increased by 63.80%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NovaBay Pharmaceuticals does not currently pay a dividend.

Dividend Growth

NovaBay Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.49% of the outstanding shares of NovaBay Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

NovaBay Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NovaBay Pharmaceuticals has recently increased by 63.80%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.02

News Sentiment

NovaBay Pharmaceuticals has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for NovaBay Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.30% of the stock of NovaBay Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 1.34% of the stock of NovaBay Pharmaceuticals is held by institutions.

NBY Stock Analysis - Frequently Asked Questions

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) released its earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.40) by $0.35. The biopharmaceutical company earned $1.84 million during the quarter. NovaBay Pharmaceuticals had a negative net margin of 79.70% and a negative trailing twelve-month return on equity of 146.20%.

When did NovaBay Pharmaceuticals' stock split?

Shares of NovaBay Pharmaceuticals reverse split on the morning of Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), Tesla (TSLA) and TherapeuticsMD (TXMD).

Company Calendar

• Last Earnings: 11/11/2021
• Today: 1/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:NBY
• CUSIP: N/A
• CIK: 1389545
• Web: novabay.com
• Phone: (510) 899-8800
• Fax: 510-474-1577
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($9.9465)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-10,610,000.00
• Net Margins: -79.70%
• Pretax Margin: -79.70%
• Return on Equity: -146.20%
• Return on Assets: -69.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.85
• Quick Ratio: 1.25

Sales & Book Value

• Annual Sales: $14.40 million
• Price / Sales: 0.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.53 per share
• Price / Book: 0.46

Miscellaneous

• Outstanding Shares: 4,210,000
• Free Float: 4,160,000
• Market Cap: $2.99 million
• Optionable: Not Optionable
• Beta: 2.82